Search results
Results from the WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
The major side effects of tegafur are similar to fluorouracil and include myelosuppression, central neurotoxicity and gastrointestinal toxicity (especially diarrhoea). [3] Gastrointestinal toxicity is the dose-limiting side effect of tegafur. [3] Central neurotoxicity is more common with tegafur than with fluorouracil. [3]
FOLFOXIRI is a chemotherapy regimen for the treatment of advanced ... the side effects of fluorouracil; F – fluorouracil (5-FU), ... m2 IV, plus oxaliplatin 85 ...
Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. [3] By intravenous injection it is used for treatment of colorectal cancer , oesophageal cancer , stomach cancer , pancreatic cancer , breast cancer , and cervical cancer . [ 3 ]
Tegafur/uracil (abbreviation: UFT [1]) is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer.. UFT is an oral formulation combining uracil (a competitive inhibitor of dihydropyrimidine dehydrogenase), and tegafur (a bioavailable 5-fluorouracil (5-FU) prodrug) in a 4:1 molar ratio.
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Adjuvant treatment in patients with stage III colon cancer is recommended [2] for 12 cycles, every two weeks. The recommended dose schedule is as follows: Day 1: Oxaliplatin 85 mg/m 2 intravenous (IV) infusion in 250-500 mL D5W and leucovorin 200 mg/m 2 IV infusion in D5W administered concurrently over 120 minutes in separate bags using a Y-line, followed by fluorouracil (5-FU) 400 mg/m 2 IV ...